Evolent Health Inc. (NYSE:EVH) insider Chad Pomeroy sold 55,180 shares of Evolent Health stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $21.54, for a total value of $1,188,577.20. Following the transaction, the insider now owns 286,370 shares in the company, valued at $6,168,409.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Evolent Health Inc. (NYSE:EVH) opened at 22.71 on Tuesday. The company’s market capitalization is $1.37 billion. The firm’s 50-day moving average price is $24.35 and its 200 day moving average price is $17.14. Evolent Health Inc. has a 52 week low of $8.14 and a 52 week high of $26.84.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.04. The company had revenue of $56.50 million for the quarter, compared to the consensus estimate of $51.96 million. Evolent Health had a negative return on equity of 5.04% and a negative net margin of 76.55%. The firm’s revenue for the quarter was up 443.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.95) EPS. Equities analysts predict that Evolent Health Inc. will post ($0.54) EPS for the current year.

Several equities analysts recently weighed in on the company. Canaccord Genuity reiterated a “buy” rating and set a $30.00 target price on shares of Evolent Health in a research report on Sunday, August 7th. FBR & Co boosted their price objective on Evolent Health from $16.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, July 13th. Jefferies Group started coverage on Evolent Health in a research report on Tuesday, July 26th. They issued a “buy” rating and a $28.00 price objective on the stock. Finally, Leerink Swann restated an “outperform” rating and issued a $20.00 price objective on shares of Evolent Health in a research report on Sunday, July 17th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $22.50.

A number of large investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. increased its stake in shares of Evolent Health by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 42,784 shares of the company’s stock valued at $822,000 after buying an additional 504 shares in the last quarter. Nationwide Fund Advisors increased its stake in shares of Evolent Health by 8.5% in the second quarter. Nationwide Fund Advisors now owns 10,109 shares of the company’s stock valued at $194,000 after buying an additional 789 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Evolent Health by 1.3% in the first quarter. Geode Capital Management LLC now owns 75,085 shares of the company’s stock valued at $792,000 after buying an additional 948 shares in the last quarter. American International Group Inc. increased its stake in shares of Evolent Health by 14.9% in the second quarter. American International Group Inc. now owns 8,761 shares of the company’s stock valued at $168,000 after buying an additional 1,134 shares in the last quarter. Finally, Salem Investment Counselors Inc. increased its stake in shares of Evolent Health by 12.9% in the second quarter. Salem Investment Counselors Inc. now owns 27,080 shares of the company’s stock valued at $520,000 after buying an additional 3,100 shares in the last quarter. 42.07% of the stock is currently owned by institutional investors.

Evolent Health Company Profile

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

5 Day Chart for NYSE:EVH

Receive News & Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.